Hepatitis C treatment with triple therapy in a patient with hemophilia A

作     者：Gurshawn Singh Reuben Sass Rayan Alamiry Nizar Zein Naim Alkhouri 

作者机构：Department of Internal MedicineCleveland Clinic FoundationClevelandOH 44195United States Digestive Disease InstituteCleveland Clinic FoundationClevelandOH 44195United States 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2013年第1卷第3期

页      面：106-107页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Hepatitis C virus Hemophilia FactorⅧ Telaprevir FactorⅧinhibitor Protease inhibitor 

摘      要：We report a case of successful treatment of chronic hepatitis C infection with telaprevir-based triple therapy in a patient with hemophilia A complicated by factor Ⅷ inhibitor. A twenty-two years old male with hereditary hemophilia A and high-titer factor Ⅷ inhibitor was taking maintenance doses of recombinant factor Ⅷ. He visited our clinic for treatment of his chronic hepatitis C with the newly instituted protease inhibitor based therapy. He was diagnosed with hepatitis C genotype 1a at one year of age. He was initiated on telaprevir, ribavirin and peg-interferon for treatment of hepatitis C and qualified for response-guided therapy. He completed treatment at 24 wk with minimal adverse effects. Notably, after 4 wk of hepatitis C treatment, his factor Ⅷ inhibitor screen was negative and the dose for recombinant factor Ⅷ decreased by half of the initial dosing before he was treated for hepatitis C. We suspect that suppressing hepatitis C may help decrease factor Ⅷ inhibitor level and the need for recombinant factor Ⅷ.